Replies to post #4603 on DNAprint Genomics (DNAG)

[IVRT]

blue, according to your post 3839, you know why!
IVRT

[SlopsterSlasher]

bluedodge51, I'll take a stab at it. My conjector is.

1} All the BIG buyers want to see Strong Revenue each Qt. and they want to see it consistent, how many time io dont know enough to show Dnap's Revenue is stable.

2}Product development complete. Right now we only have 1/4 of the Forensics package complete. Big Buyers and investors are looking for a complete 100% product.

3} We have no certification with the law enforcement or for clinical genotyping. All of which we will have soon but for now not having it doesn't help the pps.

4} No FDA approval on any thing but soon to come.

I'm sure there are other reasons some here can list a few. But these 4 will move the pps one way or the other.

[ice1051]

blue
Another reason is the large amount of issued shares. When products and revenues increase and DNAP can turn a profit this problem of a low pps will take care of itself.
ice
ps the when part could be in a few months or a few years

[spook]

(blue) It's because the market want more than flashy looking news. Revenues are the key.

Also, the massive dilution coupled with heavy inside selling we've seen for years is the main reason the price hasn't moved. Why buy at .06 when the company was selling at .02-.03?

_spook